2013-09-13 11:10:21 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research
Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tuberculosis. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
- www.fastmr.com/prod/675185_tuberculosis_pipeline_review_h2_2013. ..
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for
the indicated disease.
* A snapshot of the global therapeutic scenario for Tuberculosis.
* A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Tuberculosis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to Get this Report
* Identify and understand important and diverse types of therapeutics under development for Tuberculosis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: Johnson & Johnson, Sequella, Inc., Sanofi-Aventis, AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Piramal Healthcare Limited, Achillion Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, AVI BioPharma Inc., Crucell N.V., Hollis-Eden Pharmaceuticals, Inc., Transgene SA, Summit Corporation plc, Immune Network Research Ltd., Advinus Therapeutics Pvt. Ltd., Snowdon Inc., Statens Serum Institut, ImmunoBiology Limited, Recipharm AB, Pt. Bio Farma, MicuRx Pharmaceuticals, Inc., Mondobiotech Holding AG, Okairos, EpiVax, Inc., Archivel Farma S.L., Chimerix, Inc., Pharminox Limited, ImmunoVaccine Technologies Inc., BT PHARMA, Canopus BioPharma Incorporated, TVAX Biomedical, LLC, Medisyn Technologies, Inc., Vakzine Projekt Management GmbH, Ensoltek Co., Ltd., B&C Biopharm, GlaxoSmithKline Inc., NeED Pharma s.r.l., Vichem Chemie Research Ltd., ISA Pharmaceuticals B.V., Lipotek Pty Ltd
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
An Overview of Pipeline Products for Tuberculosis
Tuberculosis Therapeutics under Development by Companies
Tuberculosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Tuberculosis Therapeutics - Products under Development by Companies
Tuberculosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Tuberculosis Therapeutics Development
Johnson & Johnson
Eli Lilly and Company
Piramal Healthcare Limited
Achillion Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated
AVI BioPharma Inc.
Hollis-Eden Pharmaceuticals, Inc.
Summit Corporation plc
Immune Network Research Ltd.
Advinus Therapeutics Pvt. Ltd.
Statens Serum Institut
Pt. Bio Farma
MicuRx Pharmaceuticals, Inc.
Mondobiotech Holding AG
Archivel Farma S.L.
ImmunoVaccine Technologies Inc.
Canopus BioPharma Incorporated
TVAX Biomedical, LLC
Medisyn Technologies, Inc.
Vakzine Projekt Management GmbH
Ensoltek Co., Ltd.
NeED Pharma s.r.l.
Vichem Chemie Research Ltd.
ISA Pharmaceuticals B.V.
Lipotek Pty Ltd
Tuberculosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
delamanid - Drug Profile
delamanid - Drug Profile
SND-159 - Drug Profile
bedaquiline fumarate - Drug Profile
SQ-109 - Drug Profile
Tuberculosis Vaccine - Drug Profile
rifalazil - Drug Profile
SQ-609 - Drug Profile
NasL3/HtkBCG Vaccine - Drug Profile
MTBVAC01 - Drug Profile
sutezolid - Drug Profile
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.